Novo Nordisk doubles down

Novo Nordisk is spending $4.1 billion in North Carolina at the same moment cheaper copies of its star ingredient are spreading in India. That is the opposite of a retreat: it is a bet that the bottleneck in this business is still making enough drug, fast enough, in the United States. (novonordisk-us.com) The new project is a sterile manufacturing and finishing plant in Clayton, North Carolina, and Novo Nordisk says it will be the largest life science investment in that state’s history. The company says the site will add 1,000 jobs and expand a North Carolina footprint that already includes more than 2,000 employees. (novonordisk-us.com) Novo Nordisk is not building from scratch in the United States. The company says Clayton has been its biggest American manufacturing base for more than 30 years, and this latest expansion is its ninth in North Carolina after nearly $6 billion of earlier investment there. (novonordisk-us.com) The pressure point is semaglutide, the ingredient behind Ozempic and Wegovy. In India, Novo Nordisk’s patent on semaglutide expired in March 2026, and that opened the door for a rush of local drugmakers to launch lower-priced versions. (cnbc.com) India matters because it is both a giant diabetes market and a giant generic-drug factory. CNBC, citing Pharmarack data, says about 100 million people in India live with diabetes, while the country supplies roughly 20% of the world’s generic medicines. (cnbc.com) The first wave came fast. Business Standard reported that at least 10 pharmaceutical companies moved into semaglutide in India within days of patent expiry, including Dr. Reddy’s, Sun Pharma, Zydus, Natco, Alkem, and Torrent. (business-standard.com) Those launches are not niche copies sold at tiny discounts. A legal industry roundup said Dr. Reddy’s launched its generic semaglutide pen at about 4,200 Indian rupees per month, and Emcure later cut the monthly price of its brand Poviztra to 3,999 rupees from April 3. (pearceip.law) (msn.com) The early scoreboard in India is messy. CNBC reported that Eli Lilly’s share of the glucagon-like peptide 1 market there fell to 56% in March from 61% in February, while Novo Nordisk held at 25% after cutting prices on Ozempic and Wegovy to defend its position. (cnbc.com) At the same time, Eli Lilly is opening a new lane in the United States with a pill instead of a shot. Amazon Pharmacy said on April 9 that it now offers Lilly’s once-daily oral glucagon-like peptide 1 drug Foundayo, with home delivery and future pickup through clinic kiosks. (finance.yahoo.com) That changes the fight from one problem to two. Novo Nordisk is dealing with copycat pricing in India while also facing a new American distribution push that makes Lilly’s obesity drug easier to get without a refrigerated injection box. (finance.yahoo.com) (cnbc.com) So the $4.1 billion North Carolina move looks less like a victory lap and more like fortifying the home base. Novo Nordisk is putting money into sterile production lines and finished-drug capacity in the country where supply shortages, insurance coverage, and pharmacy access still decide who actually fills the prescription. (novonordisk-us.com)